These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 21496277)
21. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983 [TBL] [Abstract][Full Text] [Related]
22. AXL regulates mesothelioma proliferation and invasiveness. Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014 [TBL] [Abstract][Full Text] [Related]
23. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Linger RM; Keating AK; Earp HS; Graham DK Expert Opin Ther Targets; 2010 Oct; 14(10):1073-90. PubMed ID: 20809868 [TBL] [Abstract][Full Text] [Related]
24. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200 [No Abstract] [Full Text] [Related]
25. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations. Abdel-Rahman WM; Al-Khayyal NA; Nair VA; Aravind SR; Saber-Ayad M World J Gastroenterol; 2017 May; 23(19):3440-3448. PubMed ID: 28596680 [TBL] [Abstract][Full Text] [Related]
26. The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma. Li J; Shi C; Zhou R; Han Y; Xu S; Ma H; Zhang Z Cancer Sci; 2020 Sep; 111(9):3222-3235. PubMed ID: 32589311 [TBL] [Abstract][Full Text] [Related]
27. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Jiao Y; Ou W; Meng F; Zhou H; Wang A Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244 [TBL] [Abstract][Full Text] [Related]
28. TAZ expression as a prognostic indicator in colorectal cancer. Yuen HF; McCrudden CM; Huang YH; Tham JM; Zhang X; Zeng Q; Zhang SD; Hong W PLoS One; 2013; 8(1):e54211. PubMed ID: 23372686 [TBL] [Abstract][Full Text] [Related]
29. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival. Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455 [TBL] [Abstract][Full Text] [Related]
30. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Fridell YW; Jin Y; Quilliam LA; Burchert A; McCloskey P; Spizz G; Varnum B; Der C; Liu ET Mol Cell Biol; 1996 Jan; 16(1):135-45. PubMed ID: 8524290 [TBL] [Abstract][Full Text] [Related]
31. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Sayan AE; Stanford R; Vickery R; Grigorenko E; Diesch J; Kulbicki K; Edwards R; Pal R; Greaves P; Jariel-Encontre I; Piechaczyk M; Kriajevska M; Mellon JK; Dhillon AS; Tulchinsky E Oncogene; 2012 Mar; 31(12):1493-503. PubMed ID: 21822309 [TBL] [Abstract][Full Text] [Related]
33. Regulation of the Receptor Tyrosine Kinase AXL in Response to Therapy and Its Role in Therapy Resistance in Glioblastoma. Scherschinski L; Prem M; Kremenetskaia I; Tinhofer I; Vajkoczy P; Karbe AG; Onken JS Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055167 [TBL] [Abstract][Full Text] [Related]
34. Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells. Castro NE; Lange CA Breast Cancer Res; 2010; 12(4):R60. PubMed ID: 20687930 [TBL] [Abstract][Full Text] [Related]
35. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757 [TBL] [Abstract][Full Text] [Related]
36. Targeting Axl and Mer kinases in cancer. Verma A; Warner SL; Vankayalapati H; Bearss DJ; Sharma S Mol Cancer Ther; 2011 Oct; 10(10):1763-73. PubMed ID: 21933973 [TBL] [Abstract][Full Text] [Related]
37. Axl Is a Potential Cancer Prognostic Marker for the Migration and Invasion of Nasopharyngeal Carcinoma. Jiang C; Zhou L; Wang H; Zhang Q; Xu Y Adv Clin Exp Med; 2016; 25(3):531-7. PubMed ID: 27629742 [TBL] [Abstract][Full Text] [Related]
38. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells. Cross MJ; Lu L; Magnusson P; Nyqvist D; Holmqvist K; Welsh M; Claesson-Welsh L Mol Biol Cell; 2002 Aug; 13(8):2881-93. PubMed ID: 12181353 [TBL] [Abstract][Full Text] [Related]